{"id":"active-comparator-rivaroxaban-clopidogrel","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major or minor)"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban inhibits Factor Xa in the coagulation cascade, blocking thrombin generation and clot formation. Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor. Together, they provide complementary anticoagulant and antiplatelet mechanisms to reduce thrombotic events in high-risk cardiovascular conditions.","oneSentence":"This combination uses rivaroxaban (a Factor Xa inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects for thrombotic prevention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:17:31.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with high thrombotic risk"},{"name":"Stroke prevention in atrial fibrillation with acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT06901466","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-06-13","conditions":"Mitral Regurgitation","enrollment":880},{"nctId":"NCT03273322","phase":"PHASE2, PHASE3","title":"Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-09-13","conditions":"Atrial Fibrillation, Atrial Appendage, Hemorrhage","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Active Comparator: Rivaroxaban+Clopidogrel","genericName":"Active Comparator: Rivaroxaban+Clopidogrel","companyName":"Chinese Academy of Medical Sciences, Fuwai Hospital","companyId":"chinese-academy-of-medical-sciences-fuwai-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses rivaroxaban (a Factor Xa inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects for thrombotic prevention. Used for Acute coronary syndrome with high thrombotic risk, Stroke prevention in atrial fibrillation with acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}